TVTX Stock — Travere Therapeutics, Inc.

Up next

Next earnings call

Nov 1, 2026 Est · unconfirmed · in 7 wks

Latest filing: 10-Q

filed Aug 4, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$591.33M

Trailing 12 months

Net income (TTM)

−$43.46M

Trailing 12 months

Revenue growth YoY

+48.2%

Year over year

Operating margin

-6.8%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+5.1%

Year over year · more shares

Price change (1Y)

+147.2%

Trailing year

Short interest

12.7%

Latest settlement · 9.6 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 4, 2026

Q2 FY26

TL;DR. Travere reported strong Q2 2026 with FILSPARI U.S. net product sales up 96% year-over-year to $141.1 million driven by an early FSGS launch and continued IgAN growth, while advancing the pegtibatinase HARMONY Phase 3 (topline 2H 2027), in-licensing civorebrutinib for $112.5M upfront, and closing a convertible note refinancing that added ~$158M net proceeds.

Bullish

+ FILSPARI U.S. net product sales grew 96% year-over-year to $141.1 million in Q2 2026.
+ Pegtibatinase Phase 3 HARMONY Study continues enrollment with topline data expected in 2H 2027.
+ Pipeline expanded via closing of exclusive civorebrutinib licensing deal with Everest Medicines in July 2026.
+ USPTO issued a Notice of Allowance for a U.S. patent application directed to methods of using FILSPARI in IgA nephropathy, expected to provide coverage into October 2037.

Bearish

− Operating expenses rose materially, with SG&A up to $96.1 million from $62.6 million year-over-year and R&D up to $60.3 million from $49.4 million, reflecting launch costs and Harmony study investment.
− The $112.5 million upfront payment to Everest Medicines for civorebrutinib was paid in July 2026, reducing cash post-quarter-end.
− Gross-to-net discounts for FILSPARI are expected to rise in Q3 and Q4 as more FSGS patients initiate therapy with higher CMS utilization, despite full-year guidance maintained at mid-20%.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol High

Market backdrop VIX 15.8 · calm Equity put/call 0.60

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +54%

above

Price vs 50-day avg +9%

above

RSI (14) 57

neutral

MACD trend Negative

52-week position 97%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +8%

trailing

6-month return +147%

trailing

YTD return +73%

this year

Relative strength +129%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $61 › 200d $43 — 50d above 200d

Institutional flow Accumulating

+20% holders QoQ · +88 funds added

Insider flow Distributing

Net -$42.6K over 90 days · 100% sells

Short interest Rising

12.74% of float · ▲ +0.5% MoM · 9.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

319 holders — near 3-yr high, broad support

Squeeze score 85

high risk · 0–100

Fundamentals

Excellent

EPS growth +93%

Y/Y

Free cash flow $37.1M

Quant / Vol

risk profile

High

Volatility 65%

annualized · 1-yr

Max drawdown −33%

past year

ATR 3.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Jun 30, 2026

Peak revenue opportunity across FSGS and IgA nephropathy · peak at least $3B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+54% Bullish

Price vs 50-day avg

+9% Bullish

RSI (14)

57 Neutral

MACD trend

Negative Bearish

52-week position

97% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $61 › 200d $43 — 50d above 200d

Institutional flow Accumulating

+20% holders QoQ · +88 funds added

Insider flow Distributing

Net -$42.6K over 90 days · 100% sells

Short interest Rising

12.74% of float · ▲ +0.5% MoM · 9.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

319 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $23 Now $66 · 97% Range high $68

vs 200-day avg +54% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TVTX Travere Therapeutics, Inc. this stock	$6.43B	+73.2%	+110.5%	—	12.7%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.40B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$81.67B	+1.2%	+20.8%	19.6	2.5%
ARGX Argenx SE	$61.60B	+17.1%	—	—	2.0%
CSLLY Csl Ltd	$57.41B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

319

% held: 113.7%
Net QoQ: +1.4M sh
Top holder: Jupiter Topco LLC

Held Float

View

Held by Funds

Fund positions

306

View

Short & Settlement

Short Interest Rising

Shares short

12.0M

Days to cover: 9.6d
Change: +61.2K sh

View

Short Volume

Short vol %

64%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

78.4K

Value: $4.8M
As of: Aug 14, 2026

View

Off-Exchange

Off-exchange %

50.2%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$42.6K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Revenue (FY)

$490.7M

Net income (FY): $-25.5M
EPS diluted: $-0.29

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Aug 11, 2026
This year: 19

View

Proposed Sales

Value

$1.3M

Shares: 20.0K
Filed: Sep 10, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 11, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
TVTX	-0.6%	+7.7%	+146.5%	-0.2%	+73.2%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	+0.6%	+9.5%	+128.7%	+0.2%	+61.1%

TVTX · Travere Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance